Our attempts, combined with the initiatives of our Asian partners, are directed at demonstrating the safety and efficacy of ProLindac in multiple mixture treatment protocols for a variety of cancer types. We believe ProLindac is usually new DACH platinum chemotherapy in continued clinical development at this time. Access’ Asian partners continue to prepare regulatory and other filings in South Korea and China to commence additional combination clinical research with ProLindac. These studies are expected to provide clinical data for additional indications for ProLindac beyond late stage ovarian cancer. Additional indications under consideration include hepatocellular carcinoma, pancreatic, endometrial and others.. Gain access to Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study ACCESS PHARMACEUTICALS, INC.The company added that its drug prices in Mexico and other middle-income countries are based on several factors, including affordability, HIV incidence and government commitment to providing treatment gain access to. AHF operates treatment centers in the U.S. And additional countries, including two in Mexico . This article is usually republished with kind permission from our close friends at the The Kaiser Family Foundation. You will see the entire Kaiser Daily Health Plan Report, search the archives, or join email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Wellness Policy Report is published for Kaisernetwork.org, a free provider of The Henry J. Kaiser Family Foundation. Copyright 2007 Advisory Table Kaiser and Company Family Foundation.